Umbilical Cord/Wharton’s Jelly

Wharton’s Jelly stem cell benefits are among the most abundantly researched regenerative medicine procedures.  This is because the product can be quantified, standardized and reproduced consistently. These results showed that umbilical cord Wharton’s jelly mesenchymal stem cells (UC-MSCs):

  • had higher endothelial differentiation potential than bone marrow mesenchymal stem cells (BM-MSCs).  Therefore, umbilical cord mesenchymal stem cells (UC-MSCs) are more favorable choice than bone marrow mesenchymal stem cells (BM-MSCs) for neovascularization (the natural formation of new blood vessels) of engineered tissues.  []
  • the immune characterizations of mesenchymal stem cells, derived from Wharton’s jelly found in human umbilical cords. It was found that these cells have very low immunogenicity and good potential to tolerate rejection.  Their intermediate state between adult and embryonic stem cells makes them an ideal
    candidate for reprogramming to the pluripotent status.  [ ]
  • are safe and feasible to provide cell therapy with intravenous infusion of bone marrow‐derived mesenchymal stem cells (MSCs) to lung transplant recipients with moderate obstructive CLAD, warranting future studies to assess the effectiveness of this therapy for management of acute or chronic graft dysfunction. [ ]
  • from the human umbilical cord is a promising source of mesenchymal stem cells (HUCMSCs). Unlike bone marrow stem cells, human umbilical cord mesenchymal stem cells (HUCMSCs) have a painless collection procedure and faster self-renewal properties. This review critically evaluates their therapeutic value, challenges, and future directions for their clinical applications. [ ]
  • may provide clinical implication of oxidative stress, telomere length, DNA damage and disease has impaired the therapeutic potential of mesenchymal stem cells (MSC) isolated from aged patients. These changes in MSC biology indicate that aged patients may require an alternative source of stem cells for treatment. The high efficiency of Wharton’s Jelly mesenchymal stem cells (WJ-MSC) recovery, the minimal ethical concerns associated with its acquirement and use, low immunogenicity, and the fact that they are from healthy, young donors make them an ideal source of MSC for autologous and allogeneic applications. [ ]
  • contain the amounts of peptide growth factors calculated per microgram of DNA are distinctly higher in Wharton’s jelly in comparison to the umbilical cord artery. Western blot analysis demonstrated that almost the entire amount of these factors is bound to high molecular weight components. Since the number of cells in Wharton’s jelly is very low and the amounts of extracellular matrix components are very high, it is concluded that the cells are strongly stimulated by peptide growth factors to produce large amounts of collagen and glycosaminoglycans, which is needed for cartilage growth.                                        []

What are Stem Cells?

Stem cells are special cells in our body that can replicate and differentiate – meaning they can transform into any type of cell found in your body including but not limited to ligament, tendon, cartilage or muscle tissues. They seek out areas of injury, disease and degeneration and regenerate new, healthy cells, therefore accelerating the natural healing process. Stem cells have been especially effective in healing degenerative joint conditions.

Umbilical Stem Cells

The umbilical cord contains stem cells that are found in the umbilicus of healthy, born babies. The cells are harvested, replicated and stored then released to patients as needed. Since these cells are undifferentiated there is no risk for human cell to cell interaction. These products are monitored by the FDA and only sold to healthcare practitioners. They contain thousands of Cytokines and Growth Factors to help regenerate damaged tissues. Umbilical stem cells are safe and studies show that they are not rejected by your body.

What do umbilical cord stem cells treat?

–  Back Pain –  Neck Pain –  Joint pain
–  Shoulder pain –  Knee pain –  Hip pain
–  Foot pain –  Hand pain –  Ankle pain
–  Neuropathy –  Elbow pain –  Arthritis

What to expect during the procedure

After consulting with a regenerative specialist and finding that umbilical derived stem cells are right for you, an hour-long procedure will be scheduled. You will be asked to aggravate the joint in question 1-2 days prior to the procedure. This will turn the beacon on for the stem cells to be attracted to since they are attracted to inflammation. The cells will be removed from sub-zero and thawed. Next, they will be deployed into the degenerated joint(s).  There may be some discomfort during the cell deployment that lasts for seconds and subsides immediately.

BPI may perform one or more stem cell therapies that have not yet been approved by the FDA.  You are encouraged to consult with your primary care provider prior to undergoing a stem cell therapy.

Statement in compliance with Washington State RCW 18.130.180 February 12, 2018

OrthoBiologic procedures include: